Updates

IGL/SE/2026-27/66 6th October, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Sub: Apportionment of Cost of Acquisition of Equity Shares of India Glycols Limited (“Demerged Company”/“the Company”), Ennature Bio Pharma Limited (“Resulting Company 1”) and IGL Spirits Limited (“Resulting Company 2”) pursuant to Scheme of Arrangement amongst the Company, Resulting Company 1 and Resulting Company 2 and their respective shareholders (“Scheme”/“Scheme of Arrangement”) Dear Sir/Madam, Further to our letter bearing no. IGL/SE/2026-27/58 and IGL/SE/2026-27/59 both dated 8th September, 2026, wherein we had intimated about the allotment of equity shares of Resulting Company 1 and Resulting Company 2 pursuant to the Scheme. We enclose herewith a communication for the attention of the Shareholders of the Company for general guidance towards apportionment of cost of acquisition of equity shares of the Company, Resulting Company 1 and Resulting Company 2 pursuant to the Scheme. The above communication is also being hosted on the Company’s website at www.indiaglycols.com. This is for your information and record. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a. SCHEME OF ARRANGEMENT - GENERAL GUIDANCE FOR THE SHAREHOLDERS ON COST OF ACQUISITION 1. The Hon’ble National Company Law Tribunal, Allahabad Bench, Prayagraj (“NCLT”) vide its order dated 17th July, 2026 (“Order”), had sanctioned the Scheme of Arrangement amongst India Glycols Limited (“Demerged Company”/ “the Company”), Ennature Bio Pharma Limited (“Resulting Company 1”) and IGL Spirits Limited (“Resulting Company 2”) (Resulting Company 1 and Resulting Company 2 are hereinafter collectively referred to as the “Resulting Companies”) and their respective shareholders (“Scheme”), under the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Act”), providing, inter alia, for demerger, transfer and vesting of Bio Pharma and the Spirits & Biofuel Undertaking(s) in Resulting Company 1 and Resulting Company 2 respectively, on a going concern basis, and issue of equity shares by Resulting Company 1 and Resulting Company 2 to the shareholders of the Demerged Company, in consideration thereof as per the respective share entitlement ratio prescribed under the Scheme, in accordance with the provisions of Section 2 (35) of the Income Tax Act, 2025 (corresponding to Section 2(19AA) of the erstwhile Income-tax Act, 1961). The Scheme became effective from 1st September, 2026. 2. In accordance with the provisions of the Scheme, Resulting Company 1 and Resulting Company 2 have allotted Equity Shares of Rs. 5/- each to the shareholders of the Demerged Company whose names appeared in the Register of Members maintained by the Depositories as on the Record Date, i.e., Wednesday, 2nd September, 2026, in the following ratio: (i) 1 (One) Equity Share of Resulting Company 1 for every 3 (Three) Equity Shares held in the Demerged Company; and (ii) 1 (One) Equity Share of Resulting Company 2 for every 1 (One) Equity Share held in the Demerged Company. 3. This communication is being issued for the general guidance of the shareholders of India Glycols Limited, who have been allotted Equity Shares of Ennature Bio Pharma Limited (Resulting Company 1) and IGL Spirits Limited (Resulting Company 2) pursuant to the Scheme of Arrangement, with a view to facilitate the determination of proportionate Cost of Acquisition of the Equity Shares of India Glycols Limited, Ennature Bio Pharma Limited and IGL Spirits Limited, in accordance with the applicable provisions of the Income Tax Act, 2025. 4. Accordingly, for the purpose of determining the Cost of Acquisition of the Equity Shares of the Company and the Resulting Companies following the Demerger, the shareholders may apportion the original Cost of Acquisition of their Equity Shares of India Glycols Limited in the following manner: S. No. Name of Company % of Total Cost of Acquisition of Equity Shares 1. India Glycols Limited 31.77% 2. Ennature Bio Pharma Limited 20.61% 3. IGL Spirits Limited 47.62% Please note that this communication is merely for the general guidance of the shareholders of India Glycols Limited, who have been issued Equity Shares by Ennature Bio Pharma Limited and IGL Spirits Limited, and should not be considered as a substitute for any independent opinion that the shareholders may obtain. The concerned regulatory, statutory or judicial authority, including any assessing officer/appropriate appellate authority, could take a different view. Shareholders are advised to consult their own consultants/ tax advisors to understand specific tax implications in their respective cases. The Company takes no express or implied responsibility / liability in relation to this guidance.